OccuLogix IPO Nursed By A Lot Of TLC; Proceeds Will Fund Eye Surgery Study
This article was originally published in The Gray Sheet
Executive Summary
OccuLogix, Inc. will seek a Medicare national coverage determination for itsRheo plasma pump-and-filter system to treat "dry" age-related macular degeneration (AMD) upon FDA approval
You may also be interested in...
OccuLogix RHEO
Firm reacquires its North American patent and trademark rights to non-ophthalmic indications for the therapeutic apheresis (TA) product from Rheogenx Biosciences March 29. In exchange, OccuLogix will provide marketing support to Rheogenx subsidiary PhereSys Therapeutics after RHEO's PMA garners FDA approval, expected by mid-2006, for the treatment of "dry" age-related macular degeneration (1"The Gray Sheet" Aug. 23, 2004, p. 8). PhereSys, which plans to become the preferred mobile TA provider of RHEO, also will receive special pricing for OccuLogix pumps and disposable treatment kits related to the device...
OccuLogix RHEO
Firm reacquires its North American patent and trademark rights to non-ophthalmic indications for the therapeutic apheresis (TA) product from Rheogenx Biosciences March 29. In exchange, OccuLogix will provide marketing support to Rheogenx subsidiary PhereSys Therapeutics after RHEO's PMA garners FDA approval, expected by mid-2006, for the treatment of "dry" age-related macular degeneration (1"The Gray Sheet" Aug. 23, 2004, p. 8). PhereSys, which plans to become the preferred mobile TA provider of RHEO, also will receive special pricing for OccuLogix pumps and disposable treatment kits related to the device...
OccuLogix Conducting Rheo Clinical Trial, Crossover Studies Simultaneously
FDA approval of two open-label, multi-center crossover studies of OccuLogix' Rheo therapy for "dry" age-related macular degeneration (AMD) will provide a first look of the device's long-term efficacy